The world’s most important medical breakthrough has saved hundreds of thousands of lives worldwide.
The world has been struggling to contain the spread of the disease, and has had to rely on the best-funded and best-trained healthcare systems to cope.
Now, a Canadian medical student has come up with an innovative new way to treat people with the virus.
It was the first time anyone had been able to get people vaccinated against Ebola.
The Toronto Blue Jays announced Tuesday that the team has received two of the first two doses of a vaccine that is being distributed through a Toronto clinic that is part of the Toronto Blue Cross.
The team also received a second vaccine, the Red Cross says.
“Our community has really struggled to get the resources they need,” Dr. Michael Kain, a co-founder of the clinic, told CBC News.
“I’m a doctor, and I’m not sure how to help that.”
The clinic, which is part-owned by Toronto-based drugmaker Sanofi Pasteur, was designed to help people with respiratory infections.
It has been able get a number of people vaccinated in Toronto, including a man who died in the city in late September.
So far, only a few dozen people in Toronto have received a shot.
It is expected to be the first major vaccine distribution in Canada.
The Blue Cross says about 100 people have already been vaccinated.
The clinic is now in the process of testing and distributing the first vaccine.
Kain says the first batch of vaccine is being used to help a handful of people, including one woman who is a survivor of a previous Ebola outbreak in Liberia.
The woman’s family says the vaccine helped stop her mother, who is also a survivor, from contracting the disease.
Kains team hopes the vaccine will help a few more people to get vaccinated before the pandemic reaches its peak.
He says the company is still working on getting a large batch of the vaccine distributed to more people.
“The fact that it’s a single shot, the fact that we’re doing a small-batch vaccine, it’s an enormous leap forward,” he said.
“But it is a huge leap forward for a lot of people.”
Kain said his team will be using a vaccine manufactured by a Canadian company called Vaxiv, which has worked with the U.S. to produce the vaccine.
The vaccine will be administered through a nasal spray to help those in close contact with the patient get the vaccine as quickly as possible.